MARKET

CNSY

CNSY

Cerenome, Inc
NASDAQ
2.030
0.000
0.00%
After Hours: 2.020 -0.01 -0.49% 17:16 09/18 EDT
OPEN
2.010
PREV CLOSE
2.030
HIGH
2.100
LOW
2.000
VOLUME
60.22K
TURNOVER
--
52 WEEK HIGH
23.43
52 WEEK LOW
2.000
MARKET CAP
15.41M
P/E (TTM)
-0.4596
1D
5D
1M
3M
1Y
5Y
1D
Press Release: Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
Dow Jones · 2d ago
Weekly Report: what happened at CNSY last week (0907-0911)?
Weekly Report · 4d ago
ServiceNow To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Friday
Benzinga · 09/11 12:21
Cerenome Price Target Cut to $43.00/Share From $57.00 by Ascendiant Capital
Dow Jones · 09/11 10:11
Cerenome Is Maintained at Buy by Ascendiant Capital
Dow Jones · 09/11 10:11
Ascendiant Capital Maintains Buy on Cerenome, Lowers Price Target to $43
Benzinga · 09/11 10:01
Cerenome Secures New Senior Financing to Extend Runway
TipRanks · 09/10 12:30
Cerenome Enters Into Financing Agreement With 3i LP For Senior Secured Facility Of Up To $20M With Royalty-Based Repayments
Benzinga · 09/10 11:18
More
About CNSY
Cerenome, Inc., formerly Plus Therapeutics, Inc., is a healthcare company. The Company is focused on central nervous system (CNS) cancers through three business areas: precision diagnostics, targeted radiopharmaceutical therapeutics, and proprietary data analytics. Its subsidiary CNSide Diagnostics, LLC, develops and commercializes proprietary laboratory-developed tests, including the CNSide cerebrospinal fluid (CSF) assay platform, designed to identify, characterize and monitor tumor cells in patients with CNS cancers. Its lead product candidate, rhenium (186Re) obisbemeda (REYOBIQ), is designed for CNS cancers, including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC), through direct localized delivery utilizing tissue access methods, including convection-enhanced delivery (CED) and others. Its Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat primary and metastatic solid organ cancers.

Webull offers Cerenome, Inc. (USA) stock information, including NASDAQ: CNSY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNSY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CNSY stock methods without spending real money on the virtual paper trading platform.